

MAY. 16. 2005 1:14PM AVENTIS US PAT DEPT
TO: US USPTO GENERAL

RECEIVED
CENTRAL FAX CENTER

NO. 5240 P. 1

MAY 16 2005


PTO/SB/21 (09-04)


Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/749,630	
	Filing Date	December 31, 2003	
	First Named Inventor	Heinz-Werner KLEEMANN et al.	
	Art Unit	1625	
	Examiner Name	SEAMAN, D. Margaret M.	
Total Number of Pages in This Submission	5	Attorney Docket Number	DEAV2002/0095 US CNT

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Other Enclosure(s) (please identify below): <div style="border: 1px solid black; height: 40px; width: 100%;"></div>
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm Name	AVENTIS PHARMACEUTICALS INC.		
Signature			
Printed name	Joseph D. Rossi		
Date	May 16, 2005	Reg. No.	47,038

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: (USPTO FAX NO. 703-872-9306; Total No. of Pages Transmitted: 5)			
Signature			
Typed or printed name	Paul Irvine	Date	May 16, 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

MAY 16 2005

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICEIn re Application of
KLEEMANN, et al.

Examiner: D. M. Seaman

Application No.: 10/749,630

Art Unit: 1625

Filed: December 31, 2003

Title: 3-GUANIDINOCARBONYL-1-
HETEROARYL-PYRROLE
DERIVATIVES, PREPARATION
PROCESS, THEIR USE AS
MEDICAMENTS, AND
PHARMACEUTICAL COMPOSITIONS
COMPRISING THEM

TELEFAX CERTIFICATE

I hereby certify that this correspondence is being
transmitted via facsimile to the Commissioner for
Patents, Alexandria, VA 22313, at 703-872-9306 onDate of Transmission MAY 16, 2005
Signature [Signature]Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450RESPONSE TO RESTRICTION REQUIREMENT

Dear Sirs:

In reply to the Office Action dated April 27, 2005 ("the Action"), in which an election/restriction requirement was issued in connection with the above-identified patent application. Applicants respectfully request reconsideration of the election/restriction requirement in view of the following remarks.

Discussion of Election/Restriction Requirement Pursuant to 35 U.S.C. § 121

In the Action, the Examiner required restriction to one of the following groups of Claims under 35 U.S.C. § 121:

Group I: Claims 1 to 6, 8 to 20, 36, 38, 40, 42, 44, 46, and 48 to 49, as drawn to compounds, pharmaceutical composition, method of making and first method of use of compounds of formula (I);

- Group II: Claims 7, 22 to 33, 37, 39, 41, 43, 45, and 47, as drawn to pharmaceutical composition and method of treatment using a compounds of formula (I) plus another active ingredient;
- Group III: Claim 21 as drawn to a diagnostic agent using a compound of formula (I);
- Group IV: Claim 34 as drawn to a diagnostic agent using a compound of formula (I) plus another active ingredient; and
- Group V: Claim 35 as drawn to a method for reducing side effects using a compound of formula (I).

Solely to be responsive to the requirement for restriction, Applicants provisionally elect, **WITH TRAVERSAL**, to prosecute the Claims of **Group I**, *i.e.*, claims 1 to 6, 8 to 20, 36, 38, 40, 42, 44, 46, and 48 to 49, drawn to compounds, pharmaceutical compositions, a method of making, and a first method of use of compounds of formula (I). Furthermore, Applicants respectfully request reconsideration of the Requirement for Restriction, or in the alternative, modification of the Requirement for Restriction to allow prosecution of more than one group of claims designated by the Examiner for reasons herein provided.

For a restriction requirement to be proper, the Examiner must show that a serious burden exists if the claims of Groups I-V are examined together. M.P.E.P. § 803 (8th ed., August 2001). The Action, however, fails to make such showing.

Applicants submit respectfully that the Action provides *no* evidence or reasoning to support the election/restriction requirement or to show that the requisite serious burden exists. Indeed, the Action does not even show that each of the above-identified groups has attained recognition in the art as requiring separate fields of search.

Upon closer inspection of the claims, it is indeed reasonable to conclude that examining all of the claims together would *not* impose a serious burden. Applicants submit respectfully that all of the pending claims represented by Groups I to V recite a compound of

formula (I). Accordingly, the Examiner is faced with a *simplified* search in that, by examining the compound of formula (I), the searcher will not have to differentiate between searches specific to different methods or compositions comprising a compound of formula (I). Thus, a search for compounds of formula (I) should be all-inclusive with respect to the claimed subject matter thereby making it easier (rather than burdensome) to search.

The Action further asserts that "the inventions listed as Groups 1-5 do not relate to a single inventive concept under PCT Rule 13.1 because ... they [allegedly] lack the same or corresponding special technical feature [in that] Groups 2 and 4 need to have the compound of formula (I) plus another active ingredient() [and] Groups 1, 3 and 5 have different methods of use that can be used separately" (Action at 2). Applicants disagree respectfully as all of the pending claims *do* indeed share the same or corresponding special technical feature, *i.e.*, *a compound of formula (I)*. Moreover, even if the inventions of Groups I to V are independent or distinct as alleged by the Action, whether restriction is proper still depends upon whether a serious burden exists:

[i]f the search and examination of an entire application can be made without serious burden, the examiner must examine it on the merits, even though it includes claims to independent or distinct inventions.

(M.P.E.P. § 803 (8th ed., August 2001). For the reasons detailed above, Applicants respectfully submit that the examination of all of the claims pending in the present application would *not* present an undue burden on the Examiner. Accordingly, withdrawal of the election/restriction requirement or, in the alternative a modification thereof, is respectfully requested.